menu
    • menu
    [{"orgOrder":0,"company":"Ivy Brain Tumor Center","sponsor":"BridgeBio Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Infigratinib","moa":"Fibroblast growth factor receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Ivy Brain Tumor Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ivy Brain Tumor Center \/ Ivy Brain Tumor Center","highestDevelopmentStatusID":"6","companyTruncated":"Ivy Brain Tumor Center \/ Ivy Brain Tumor Center"},{"orgOrder":0,"company":"Ivy Brain Tumor Center","sponsor":"BeOne Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pamiparib","moa":"||Poly [ADP-ribose] polymerase 2 | Poly [ADP-ribose] polymerase-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ivy Brain Tumor Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ivy Brain Tumor Center \/ Ivy Brain Tumor Center","highestDevelopmentStatusID":"7","companyTruncated":"Ivy Brain Tumor Center \/ Ivy Brain Tumor Center"},{"orgOrder":0,"company":"Ivy Brain Tumor Center","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"Poly [ADP-ribose] polymerase-1 | Poly [ADP-ribose] polymerase 2","graph1":"Oncology","graph2":"Phase III","graph3":"Ivy Brain Tumor Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ivy Brain Tumor Center \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Ivy Brain Tumor Center \/ GSK"},{"orgOrder":0,"company":"Ivy Brain Tumor Center","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Collaboration","leadProduct":"Niraparib Tosylate","moa":"Poly [ADP-ribose] polymerase-1 | Poly [ADP-ribose] polymerase 2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ivy Brain Tumor Center","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ivy Brain Tumor Center \/ GSK","highestDevelopmentStatusID":"5","companyTruncated":"Ivy Brain Tumor Center \/ GSK"},{"orgOrder":0,"company":"Ivy Brain Tumor Center","sponsor":"Vivace Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"VT-01","moa":"TEAD palmitoylation","graph1":"Oncology","graph2":"Preclinical","graph3":"Ivy Brain Tumor Center","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ivy Brain Tumor Center \/ Ivy Brain Tumor Center","highestDevelopmentStatusID":"4","companyTruncated":"Ivy Brain Tumor Center \/ Ivy Brain Tumor Center"}]

    Find Clinical Drug Pipeline Developments & Deals by Ivy Brain Tumor Center

    Menu

    Ivy Brain Tumor Center

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ivy Brain Tumor Center

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed

                            Ivy Brain Tumor Center

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Niraparib Tosylate

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : GSK

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Gl...

                            Details : Niraparib is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Glioblastoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 29, 2024

                            Lead Product(s) : Niraparib Tosylate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : GSK

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Ivy Brain Tumor Center

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed

                            Ivy Brain Tumor Center

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pamiparib,Temozolomide

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : BeOne Medicines

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ivy Brain Tumor Center Announces Initial Results of Pamiparib in Newly-Diagnosed and Recurrent Glioblastoma at...

                            Details : The interim analysis demonstrated that pamiparib is well-tolerated in glioblastoma patients, reaches pharmacologically-relevant concentrations in nonenhancing GBM tissue, and sensitizes brain tumor tissue to radiation ex vivo.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 10, 2022

                            Lead Product(s) : Pamiparib,Temozolomide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : BeOne Medicines

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ivy Brain Tumor Center

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed

                            Ivy Brain Tumor Center

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Niraparib Tosylate

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : GSK

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Ivy Brain Tumor Center Collaborates with GSK on New Phase 0 Clinical Trial to Evaluate Niraparib in Patients w...

                            Details : The launch of the Phase 0 clinical trial with niraparib will begin by enrolling six Arm A participants to determine the Optimal Time Interval (OTI) and the tumor resection that can detect maximum unbound drug concentration in the gadolinium nonenhancing ...

                            Product Name : Zejula

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Undisclosed

                            October 22, 2021

                            Lead Product(s) : Niraparib Tosylate

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : GSK

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Ivy Brain Tumor Center

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed

                            Ivy Brain Tumor Center

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VT-01

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Vivace Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Ivy Brain Tumor Center and Vivace Therapeutics Collaborate to Test Targeted Agent in Glioblastoma and Meningio...

                            Details : The Ivy Brain Tumor Center, which employs a bold, early-phase clinical trials strategy, will evaluate Vivace’s novel development compound, VT-01, as an experimental therapy in two aggressive forms of brain cancer – glioblastoma and meningioma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            August 26, 2020

                            Lead Product(s) : VT-01

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Vivace Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Ivy Brain Tumor Center

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed

                            Ivy Brain Tumor Center

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Infigratinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : BridgeBio Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ivy Brain Tumor Center and QED Therapeutics Announce Dosing of First Patient in a Phase 0/2 Trial of Infigrati...

                            Details : Precision medicine study designed to confirm infigratinib's ability to cross blood-brain barrier and hit molecular targets in high-grade glioma patients with FGFR genetic alterations.

                            Product Name : Truseltiq

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 28, 2020

                            Lead Product(s) : Infigratinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : BridgeBio Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth